BMS option pact injects new life into Biocon's oral insulin

Biocon has entered into an agreement with Bristol-Myers Squibb, under which the US multinational holds an exclusive option to further develop and commercialize the Indian firm's prandial oral insulin candidate, IN-105, pending the outcome of certain clinical trials.